Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysisKazem Rahimi, Takayoshi Ohkubo, Barry R. Davis et al.|The Lancet|2021Cited by 997
GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug AdministrationAndrew S. Levey, Josef Coresh, Lesley A. Inker et al.|American Journal of Kidney Diseases|2014Cited by 597
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trialsHiddo J.L. Heerspink, Tom Greene, Hocine Tighiouart et al.|The Lancet Diabetes & Endocrinology|2019Cited by 372